http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 06 Mar 2026 12:19:02 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Jefferies+Reiterates+Buy+Rating+on+aTyr+Pharma+%28ATYR%29%3A+%22view+an+immediate+approval+of+EFZO%E2%80%91FIT+as+low+probability%22/26123965.html <p>Jefferies analyst Roger Song reiterated a Buy rating and $3.00 price target on aTyr Pharma (NASDAQ: ATYR)</p><p>The analyst commented, "Our thesis remains that efzofitimod shows a signal on symptom/QoL measures (KSQ‑L and related PROs) with acceptable tolerability (NOTE), but the EFZO‑FIT miss forces a regulatory re‑framing: Steroids are becoming a less viable 1EP as practice shifts toward minimal chronic OCS use, increasing the probability that FDA requires a new, adequately controlled trial anchored on “feel/function” measures (lung function ± PRO). The key questions are (i) whether FDA will accept a single additional well‑controlled study with a lung function and/or PRO‑centric http://www.streetinsider.com/Analyst+Comments/Jefferies+Reiterates+Buy+Rating+on+aTyr+Pharma+%28ATYR%29%3A+%22view+an+immediate+approval+of+EFZO%E2%80%91FIT+as+low+probability%22/26123965.html Fri, 06 Mar 2026 12:19:02 -0500 ATYR http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Neutral+Rating+on+aTyr+Pharma+%28ATYR%29%3A+%22viewing+the+upcoming+1Q26+Type+C+meeting+with+the+FDA+as+a+critical+catalyst%22/26122563.html <p>H.C. Wainwright analyst Joseph Pantginis reiterated a Neutral rating and {REMOVEPT} price target on aTyr Pharma (NASDAQ: ATYR)</p><p>The analyst commented, "With this update, we maintain our Neutral rating as the company is now a 'show me' story, in our view, following the Phase 3 EFZO-FIT study not meeting its primary endpoint for efzofitimod in pulmonary sarcoidosis. We are viewing the upcoming 1Q26 Type C meeting with the FDA as a critical catalyst to determine whether there is a viable path forward for efzofitmod. The company continues to advance efzofitimod in the Phase 2 EFZO-CONNECT study in SSc-ILD."</p><p>For an analyst ratings http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Neutral+Rating+on+aTyr+Pharma+%28ATYR%29%3A+%22viewing+the+upcoming+1Q26+Type+C+meeting+with+the+FDA+as+a+critical+catalyst%22/26122563.html Fri, 06 Mar 2026 08:31:06 -0500 ATYR http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++aTYR+PHARMA+INC+++++++++++For%3A+Dec+31/26119001.html si-local-file:///var/storage/secattach/20260305/26119001.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++aTYR+PHARMA+INC+++++++++++For%3A+Dec+31/26119001.html Thu, 05 Mar 2026 16:12:00 -0500 ATYR O.03091282 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++aTYR+PHARMA+INC+++++++++++For%3A+Dec+31/26119001.html si-local-file:///var/storage/secattach/20260305/26119001.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++aTYR+PHARMA+INC+++++++++++For%3A+Dec+31/26119001.html Thu, 05 Mar 2026 16:12:00 -0500 ATYR O.03091282 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++aTYR+PHARMA+INC+++++++++++For%3A+Mar+05/26118716.html si-local-file:///var/storage/secattach/20260305/26118716.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++aTYR+PHARMA+INC+++++++++++For%3A+Mar+05/26118716.html Thu, 05 Mar 2026 16:04:00 -0500 ATYR O.03091282 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++aTYR+PHARMA+INC+++++++++++For%3A+Mar+05/26118716.html si-local-file:///var/storage/secattach/20260305/26118716.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++aTYR+PHARMA+INC+++++++++++For%3A+Mar+05/26118716.html Thu, 05 Mar 2026 16:04:00 -0500 ATYR O.03091282 http://www.streetinsider.com/Press+Releases/aTyr+Pharma+Announces+Fourth+Quarter+and+Full+Year+2025+Results+and+Provides+Corporate+Update/26118628.html <p align="center"><em>Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. </em></p> <p align="center"><em>Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) on track to complete enrollment in the first half of 2026.</em></p> <p align="center"><em>Ended 2025 with $80.9 million in cash, cash equivalents, restricted cash and investments.</em></p> <p align="justify">SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in http://www.streetinsider.com/Press+Releases/aTyr+Pharma+Announces+Fourth+Quarter+and+Full+Year+2025+Results+and+Provides+Corporate+Update/26118628.html Thu, 05 Mar 2026 16:01:00 -0500 A.06822034 A.50212082 ATYR O.03091282 O.14919718 O.20026344 http://www.streetinsider.com/Press+Releases/aTyr+Pharma+Announces+Fourth+Quarter+and+Full+Year+2025+Results+and+Provides+Corporate+Update/26118628.html <p align="center"><em>Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. </em></p> <p align="center"><em>Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) on track to complete enrollment in the first half of 2026.</em></p> <p align="center"><em>Ended 2025 with $80.9 million in cash, cash equivalents, restricted cash and investments.</em></p> <p align="justify">SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in http://www.streetinsider.com/Press+Releases/aTyr+Pharma+Announces+Fourth+Quarter+and+Full+Year+2025+Results+and+Provides+Corporate+Update/26118628.html Thu, 05 Mar 2026 16:01:00 -0500 A.06822034 A.50212082 ATYR O.03091282 O.14919718 O.20026344 http://www.streetinsider.com/Press+Releases/aTyr+Pharma+Announces+Fourth+Quarter+and+Full+Year+2025+Results+and+Provides+Corporate+Update/26118628.html <p align="center"><em>Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. </em></p> <p align="center"><em>Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) on track to complete enrollment in the first half of 2026.</em></p> <p align="center"><em>Ended 2025 with $80.9 million in cash, cash equivalents, restricted cash and investments.</em></p> <p align="justify">SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in http://www.streetinsider.com/Press+Releases/aTyr+Pharma+Announces+Fourth+Quarter+and+Full+Year+2025+Results+and+Provides+Corporate+Update/26118628.html Thu, 05 Mar 2026 16:01:00 -0500 A.06822034 A.50212082 ATYR O.03091282 O.14919718 O.20026344 http://www.streetinsider.com/Press+Releases/aTyr+Pharma+Announces+Fourth+Quarter+and+Full+Year+2025+Results+and+Provides+Corporate+Update/26118628.html <p align="center"><em>Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. </em></p> <p align="center"><em>Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) on track to complete enrollment in the first half of 2026.</em></p> <p align="center"><em>Ended 2025 with $80.9 million in cash, cash equivalents, restricted cash and investments.</em></p> <p align="justify">SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in http://www.streetinsider.com/Press+Releases/aTyr+Pharma+Announces+Fourth+Quarter+and+Full+Year+2025+Results+and+Provides+Corporate+Update/26118628.html Thu, 05 Mar 2026 16:01:00 -0500 A.06822034 A.50212082 ATYR O.03091282 O.14919718 O.20026344 http://www.streetinsider.com/Press+Releases/aTyr+Pharma+Announces+Fourth+Quarter+and+Full+Year+2025+Results+and+Provides+Corporate+Update/26118628.html <p align="center"><em>Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. </em></p> <p align="center"><em>Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) on track to complete enrollment in the first half of 2026.</em></p> <p align="center"><em>Ended 2025 with $80.9 million in cash, cash equivalents, restricted cash and investments.</em></p> <p align="justify">SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in http://www.streetinsider.com/Press+Releases/aTyr+Pharma+Announces+Fourth+Quarter+and+Full+Year+2025+Results+and+Provides+Corporate+Update/26118628.html Thu, 05 Mar 2026 16:01:00 -0500 A.06822034 A.50212082 ATYR O.03091282 O.14919718 O.20026344 http://www.streetinsider.com/Press+Releases/aTyr+Pharma+Announces+Fourth+Quarter+and+Full+Year+2025+Results+and+Provides+Corporate+Update/26118628.html <p align="center"><em>Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. </em></p> <p align="center"><em>Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) on track to complete enrollment in the first half of 2026.</em></p> <p align="center"><em>Ended 2025 with $80.9 million in cash, cash equivalents, restricted cash and investments.</em></p> <p align="justify">SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in http://www.streetinsider.com/Press+Releases/aTyr+Pharma+Announces+Fourth+Quarter+and+Full+Year+2025+Results+and+Provides+Corporate+Update/26118628.html Thu, 05 Mar 2026 16:01:00 -0500 A.06822034 A.50212082 ATYR O.03091282 O.14919718 O.20026344 http://www.streetinsider.com/Globe+Newswire/aTyr+Pharma+Announces+Fourth+Quarter+and+Full+Year+2025+Results+and+Provides+Corporate+Update/26118628.html <p align="center"><em>Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. </em></p> <p align="center"><em>Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) on track to complete enrollment in the first half of 2026.</em></p> <p align="center"><em>Ended 2025 with $80.9 million in cash, cash equivalents, restricted cash and investments.</em></p> <p align="justify">SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in http://www.streetinsider.com/Globe+Newswire/aTyr+Pharma+Announces+Fourth+Quarter+and+Full+Year+2025+Results+and+Provides+Corporate+Update/26118628.html Thu, 05 Mar 2026 16:01:00 -0500 A.06822034 A.50212082 ATYR O.03091282 O.14919718 O.20026344 http://www.streetinsider.com/Globe+Newswire/aTyr+Pharma+Announces+Fourth+Quarter+and+Full+Year+2025+Results+and+Provides+Corporate+Update/26118628.html <p align="center"><em>Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. </em></p> <p align="center"><em>Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) on track to complete enrollment in the first half of 2026.</em></p> <p align="center"><em>Ended 2025 with $80.9 million in cash, cash equivalents, restricted cash and investments.</em></p> <p align="justify">SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in http://www.streetinsider.com/Globe+Newswire/aTyr+Pharma+Announces+Fourth+Quarter+and+Full+Year+2025+Results+and+Provides+Corporate+Update/26118628.html Thu, 05 Mar 2026 16:01:00 -0500 A.06822034 A.50212082 ATYR O.03091282 O.14919718 O.20026344 http://www.streetinsider.com/Globe+Newswire/aTyr+Pharma+Announces+Fourth+Quarter+and+Full+Year+2025+Results+and+Provides+Corporate+Update/26118628.html <p align="center"><em>Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. </em></p> <p align="center"><em>Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) on track to complete enrollment in the first half of 2026.</em></p> <p align="center"><em>Ended 2025 with $80.9 million in cash, cash equivalents, restricted cash and investments.</em></p> <p align="justify">SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in http://www.streetinsider.com/Globe+Newswire/aTyr+Pharma+Announces+Fourth+Quarter+and+Full+Year+2025+Results+and+Provides+Corporate+Update/26118628.html Thu, 05 Mar 2026 16:01:00 -0500 A.06822034 A.50212082 ATYR O.03091282 O.14919718 O.20026344 http://www.streetinsider.com/Globe+Newswire/aTyr+Pharma+Announces+Fourth+Quarter+and+Full+Year+2025+Results+and+Provides+Corporate+Update/26118628.html <p align="center"><em>Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. </em></p> <p align="center"><em>Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) on track to complete enrollment in the first half of 2026.</em></p> <p align="center"><em>Ended 2025 with $80.9 million in cash, cash equivalents, restricted cash and investments.</em></p> <p align="justify">SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in http://www.streetinsider.com/Globe+Newswire/aTyr+Pharma+Announces+Fourth+Quarter+and+Full+Year+2025+Results+and+Provides+Corporate+Update/26118628.html Thu, 05 Mar 2026 16:01:00 -0500 A.06822034 A.50212082 ATYR O.03091282 O.14919718 O.20026344 http://www.streetinsider.com/Globe+Newswire/aTyr+Pharma+Announces+Fourth+Quarter+and+Full+Year+2025+Results+and+Provides+Corporate+Update/26118628.html <p align="center"><em>Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. </em></p> <p align="center"><em>Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) on track to complete enrollment in the first half of 2026.</em></p> <p align="center"><em>Ended 2025 with $80.9 million in cash, cash equivalents, restricted cash and investments.</em></p> <p align="justify">SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in http://www.streetinsider.com/Globe+Newswire/aTyr+Pharma+Announces+Fourth+Quarter+and+Full+Year+2025+Results+and+Provides+Corporate+Update/26118628.html Thu, 05 Mar 2026 16:01:00 -0500 A.06822034 A.50212082 ATYR O.03091282 O.14919718 O.20026344 http://www.streetinsider.com/Globe+Newswire/aTyr+Pharma+Announces+Fourth+Quarter+and+Full+Year+2025+Results+and+Provides+Corporate+Update/26118628.html <p align="center"><em>Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. </em></p> <p align="center"><em>Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) on track to complete enrollment in the first half of 2026.</em></p> <p align="center"><em>Ended 2025 with $80.9 million in cash, cash equivalents, restricted cash and investments.</em></p> <p align="justify">SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in http://www.streetinsider.com/Globe+Newswire/aTyr+Pharma+Announces+Fourth+Quarter+and+Full+Year+2025+Results+and+Provides+Corporate+Update/26118628.html Thu, 05 Mar 2026 16:01:00 -0500 A.06822034 A.50212082 ATYR O.03091282 O.14919718 O.20026344 http://www.streetinsider.com/Press+Releases/aTyr+Pharma+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26035825.html <p align="justify">SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr’s Board of Directors has granted two employees nonstatutory stock options to purchase an aggregate of 12,200 shares of aTyr’s common stock, each with an exercise price of $0.98 per share, which is equal to the closing price of aTyr’s common stock on the Nasdaq Capital Market on February 17, 2026, the effective http://www.streetinsider.com/Press+Releases/aTyr+Pharma+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26035825.html Fri, 20 Feb 2026 16:01:00 -0500 ATYR O.03091282 http://www.streetinsider.com/Press+Releases/aTyr+Pharma+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26035825.html <p align="justify">SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr’s Board of Directors has granted two employees nonstatutory stock options to purchase an aggregate of 12,200 shares of aTyr’s common stock, each with an exercise price of $0.98 per share, which is equal to the closing price of aTyr’s common stock on the Nasdaq Capital Market on February 17, 2026, the effective http://www.streetinsider.com/Press+Releases/aTyr+Pharma+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26035825.html Fri, 20 Feb 2026 16:01:00 -0500 ATYR O.03091282 http://www.streetinsider.com/Globe+Newswire/aTyr+Pharma+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26035825.html <p align="justify">SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr’s Board of Directors has granted two employees nonstatutory stock options to purchase an aggregate of 12,200 shares of aTyr’s common stock, each with an exercise price of $0.98 per share, which is equal to the closing price of aTyr’s common stock on the Nasdaq Capital Market on February 17, 2026, the effective http://www.streetinsider.com/Globe+Newswire/aTyr+Pharma+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26035825.html Fri, 20 Feb 2026 16:01:00 -0500 ATYR O.03091282 http://www.streetinsider.com/Globe+Newswire/aTyr+Pharma+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26035825.html <p align="justify">SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr’s Board of Directors has granted two employees nonstatutory stock options to purchase an aggregate of 12,200 shares of aTyr’s common stock, each with an exercise price of $0.98 per share, which is equal to the closing price of aTyr’s common stock on the Nasdaq Capital Market on February 17, 2026, the effective http://www.streetinsider.com/Globe+Newswire/aTyr+Pharma+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26035825.html Fri, 20 Feb 2026 16:01:00 -0500 ATYR O.03091282 http://www.streetinsider.com/Press+Releases/aTyr+Pharma+to+Present+at+the+Leerink+Partners+Global+Healthcare+Conference/26018228.html <p align="justify">SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the Leerink Partners Global Healthcare Conference, which is scheduled to take place March 8 – 11, 2026, in Miami, FL.</p> <p align="justify">Details of the presentation appear below:</p> <p>Conference: Leerink Partners Global Healthcare Conference<br/>Date: Wednesday, March 11, 2026<br/>Time: 8:00am EDT<br/>Location: Miami, FL<br/>Format: Corporate Presentation</p> <p align="justify">In http://www.streetinsider.com/Press+Releases/aTyr+Pharma+to+Present+at+the+Leerink+Partners+Global+Healthcare+Conference/26018228.html Wed, 18 Feb 2026 08:00:00 -0500 ATYR O.03091282 http://www.streetinsider.com/Press+Releases/aTyr+Pharma+to+Present+at+the+Leerink+Partners+Global+Healthcare+Conference/26018228.html <p align="justify">SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the Leerink Partners Global Healthcare Conference, which is scheduled to take place March 8 – 11, 2026, in Miami, FL.</p> <p align="justify">Details of the presentation appear below:</p> <p>Conference: Leerink Partners Global Healthcare Conference<br/>Date: Wednesday, March 11, 2026<br/>Time: 8:00am EDT<br/>Location: Miami, FL<br/>Format: Corporate Presentation</p> <p align="justify">In http://www.streetinsider.com/Press+Releases/aTyr+Pharma+to+Present+at+the+Leerink+Partners+Global+Healthcare+Conference/26018228.html Wed, 18 Feb 2026 08:00:00 -0500 ATYR O.03091282 http://www.streetinsider.com/Globe+Newswire/aTyr+Pharma+to+Present+at+the+Leerink+Partners+Global+Healthcare+Conference/26018228.html <p align="justify">SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the Leerink Partners Global Healthcare Conference, which is scheduled to take place March 8 – 11, 2026, in Miami, FL.</p> <p align="justify">Details of the presentation appear below:</p> <p>Conference: Leerink Partners Global Healthcare Conference<br/>Date: Wednesday, March 11, 2026<br/>Time: 8:00am EDT<br/>Location: Miami, FL<br/>Format: Corporate Presentation</p> <p align="justify">In http://www.streetinsider.com/Globe+Newswire/aTyr+Pharma+to+Present+at+the+Leerink+Partners+Global+Healthcare+Conference/26018228.html Wed, 18 Feb 2026 08:00:00 -0500 ATYR O.03091282